vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Entera Bio Ltd. (ENTX). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral formulations of biologics and large-molecule therapies traditionally administered via injection. Its core pipeline targets treatments for rare diseases, metabolic disorders, and autoimmune conditions, serving patient populations across global markets.
ASBP vs ENTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-3.0M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -27.9% |
| EPS (diluted) | $-0.04 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $42.0K | ||
| Q4 24 | — | $82.0K | ||
| Q3 24 | — | $42.0K | ||
| Q2 24 | — | $57.0K | ||
| Q1 24 | — | $0 |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | $-1.9M | $-3.2M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $-2.4M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-2.1M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 15.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -59015.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6102.4% | ||
| Q4 24 | — | -2850.0% | ||
| Q3 24 | — | -7192.9% | ||
| Q2 24 | — | -3798.2% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -95337.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6111.9% | ||
| Q4 24 | — | -2875.6% | ||
| Q3 24 | — | -7192.9% | ||
| Q2 24 | — | -3763.2% | ||
| Q1 24 | — | — |
| Q4 25 | — | $0.06 | ||
| Q3 25 | $-0.04 | $0.07 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $13.1M |
| Total Assets | $2.4M | $16.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.1M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | — | $10.9M | ||
| Q1 25 | — | $12.6M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $6.9M | ||
| Q2 24 | — | $9.1M | ||
| Q1 24 | — | $9.2M |
| Q4 25 | — | $13.1M | ||
| Q3 25 | $-11.5M | $15.2M | ||
| Q2 25 | — | $17.3M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $8.1M | ||
| Q3 24 | — | $6.5M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $8.9M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | $2.4M | $17.4M | ||
| Q2 25 | — | $19.7M | ||
| Q1 25 | — | $21.6M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $10.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-1.9M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-1.1M | $-2.5M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.2M | ||
| Q2 24 | — | $-1.3M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | $-1.9M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3361.9% | ||
| Q4 24 | — | -1792.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 19.0% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
